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Synopsis
eNOS (endothelial nitric oxide synthase) contains a MAPK (mitogen-activated protein kinase)-binding site associated
with a major eNOS control element. Purified ERK (extracellular-signal-regulated kinase) phosphorylates eNOS with
a stoichiometry of 2–3 phosphates per eNOS monomer. Phosphorylation decreases NO synthesis and cytochrome
c reductase activity. Three sites of phosphorylation were detected by MS. All sites matched the SP and TP MAPK
(mitogen-activated protein kinase) phosphorylation motif. Ser602 lies at the N-terminal edge of the 42-residue eNOS
AI (autoinhibitory) element. The pentabasic MAPK-binding site lies at the opposite end of the AI, and other critical
regulatory features are between them. Thr46 and Ser58 are located in a flexible region associated with the N terminus
of the oxygenase domain. In contrast with PKC (protein kinase C), phosphorylation by ERK did not significantly interfere
with CaM (calmodulin) binding as analysed by optical biosensing. Instead, ERK phosphorylation favours a state in
which FMN and FAD are in close association and prevents conformational changes that expose reduced FMN to
acceptors. The close associations between control sites in a few regions of the molecule suggest that control of
signal generation is modulated by multiple inputs interacting directly on the surface of eNOS via overlapping binding
domains and tightly grouped targets.
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INTRODUCTION
Signalling networks include elaborate feedback and feed-forward
mechanisms and are responsible for homoeostasis over multiple
levels of organization. The familiar picture of signal transduc-
tion cascades in which amplification is obtained by sequential
phosphorylation/activation has been augmented by the discovery
of multi-component signalling complexes that may include re-
ceptors, kinases, scaffolds and adaptors, and non-kinase signal
generators [1–4].
eNOS (endothelial nitric oxide synthase) is a signal gener-
ator in the regulation of vascular and airway tone, insulin secre-
tion, angiogenesis and cardiac function [5–10]. Primary control
is through Ca/CaM (calmodulin) activation [11], but numerous
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other inputs have been described including inhibitory and activat-
ing phosphorylation by specific kinases, protein-protein interac-
tions and cell trafficking. [12–15] Examples of activating kinases
include PKA (protein kinase A), which phosphorylates Ser1179
and Ser635, and Akt, which phosphorylates Ser1179 and Ser617
[15–18] (The sequence numbering of human and bovine eNOSs
in the reductase regions differ by 2 amino acids; bovine Thr497
corresponds to human Thr495, bovine Ser617 and Ser635 to human
Ser615 and Ser633 and bovine Ser1179 to human Ser1177; see also
Figure 1). Ser1177 is located in the C-terminal tail, which acts to re-
strict the rate of haem reduction by the flavin containing domains
[19–22]. Ser635 and Ser617 are located in a large AI (autoinhib-
itory) insertion in the FMN-binding domain, which is displaced
by CaM binding during activation [23]. PKC (protein kinase C)
inhibits eNOS by phosphorylating Thr495 [24,25], adjacent to
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
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the CaM-binding site, which interferes with CaM-mediated ac-
tivation [26,27]. Other phosphorylation sites associated with the
oxygenase domain are less well studied.
MAPKs (mitogen-activated protein kinases), including ERK
(extracellular-signal-regulated kinase), p38 and JNK (c-Jun N-
terminal kinase) are important signalling nodes in pathways that
control metabolism, growth and expression [28–32]. ERK and
p38 both function in signalling pathways [33,34] that involve
eNOS and good evidence for direct phosphorylation of eNOS
by ERK1/2 in BAECs (bovine aortic endothelial cells) has been
obtained [35]. Contradictory reports of the site of ERK phos-
phorylation have appeared [36,37]. The uncertainty is the res-
ult of pathway-dependent phosphorylation events in which ERK
drives the activation of other kinases, since some of the proposed
sites do not match the target motifs of MAPKs, and may also re-
flect cross-talk in which phosphorylation at one position exposes
other positions to phosphorylation.
We recently identified a pentabasic-binding site for MAPKs in
the eNOS AI element [38]. Here we report the sites of ERK phos-
phorylation, the effects on activity, and the mechanism by which
phosphorylation regulates NO synthesis. The phosphorylation
sites are distinct from the D-domain-type binding site we reported
previously. The uncertainties introduced by pathway-dependent
phosphorylation events have been removed by working with pur-
ified components, but additional sites might be exposed by cova-
lent modification or protein–protein interactions in cells.
EXPERIMENTAL
Expression and purification of eNOS was carried out as previ-
ously described [37,39,40]. Prosthetic group content was meas-
ured spectrophotometrically [40]. NO synthase activity was
measured using haemoglobin capture and Griess assay, and re-
ductase activity was measured using cytochrome c reduction
[41,42]. Affinity purified, single-band ERK2 from an Escheri-
chia coli expression system was purchased from SignalChem.
ERK kinase reactions were performed in 20 mM Hepes
(pH 7.4), 1 mM DTT, 10 mM MgCl2, 1 mM ATP, 10 % (v/v)
glycerol and when using the high concentration eNOS, 0.75 mM
EGTA. eNOS was used at various concentrations (45–1.6 μM
for fluorescence and eNOS/cytochrome c experiments, respect-
ively). Reactions were done plus or minus ERK (0.12–0.01 μM,
depending on eNOS concentration) at room temperature, ∼22 ◦C
(see figure legends) and were ‘stopped’ by putting on ice until
the activity was tested; within 5 h. 0.315 nM of phosphorylated
and unphosphorylated eNOS were sent for MS analysis. MS of
trypsin digested enzyme was carried out at the Emory University
proteomics facility with duplicate phosphorylated and unphos-
phorylated samples.
Western blot analysis was done with a Li-Cor Odyssey. The
control eNOS antibody was from Invitrogen (clone 9D10). The
eNOS pS602 antibody is a peptide antibody. The phospho-
peptide, used to immunize rabbits, and the resulting antibodies
were affinity purified by NeoBioLab.
BAECs were purchased from Lonza, grown in the recom-
mended media and harvested at confluence using lysis buffer
(50 mM Tris, 150 mM NaCl, 1.5 mM MgCl2, 1 % ipegal, 0.5 %
(v/v) Triton X-100, 2 mM EDTA, HALT protease inhibitor cock-
tail (Thermo) and 1 μM microcystin LR and 200 μM Na3VO4).
Approximately 25 % of the lysate from a 10 cm plate was treated
with or without 400 units of λ phosphatase in a 50 μl reaction for
the indicated times, 20 μl was loaded on the gel.
Time-resolved intensity decays were recorded using a PTI TC-
SPC (time-correlated single-photon counting) fluorescence life-
time spectrometer as described [43]. FMN was excited at 473 nm
using a pulsed laser diode with 20 MHz repetition rate; experi-
ments with 378 nm excitation produced similar results. The decay











where the τ i are the decay times and αi are the amplitudes of the
ith component. The fractional contribution of the ith component




Individual values of αi and τ i were determined from simula-
tion with PTI’s Felix GX software with PowerFit 10 simulation
module, using deconvolution of an instrument response function
obtained from scattering and nonlinear least squares fitting to
multiple exponentials. The quality of these fits were character-
ized by ϕ2. Additional information is available in [44].
BLI (biolayer interferometry) experiments were conducted es-
sentially as described in [27]. Briefly, biotinylated CaM was im-
mobilized on streptavidin sensors. After establishing a baseline
in binding buffer (10 mM HEPES, pH 7.4, 100 mM NaCl, 10 %
glycerol, 10 μM CaCl2 and 0.05 % surfactant P-20), sensors were
moved to binding the buffer containing eNOS for 180 s. Sensors
were then moved to the buffer only to monitor dissociation for
180 s. Non-specific binding was measured by immersing sensors
without CaM in analyte and was negligible in all cases. All bio-
sensing experiments were performed at 25 ◦C.
SPR (surface plasmon resonance) experiments were conduc-
ted on a Biacore X100 instrument using a biotin CAPture chip.
Biotinylated CaM (∼150 RU in all cases) was immobilized prior
to single-cycle kinetics performed in the binding buffer.
RESULTS
Figure 1 shows the alignment of the DNA and amino acid se-
quences of mammalian NOS (nitric oxide synthase) isoforms in
a region corresponding to an α–β turn within the Rossmann-
fold FMN-binding domain. The signal generators eNOS and
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ERK phosphorylates and inhibits eNOS
Figure 1 Sequence alignment of NOS mammalian isoforms in the AI element region
Note conserved region (bold) and frame shifts causing divergence of the variable region in eNOS and nNOS. Helix residues
are underlined. Phosphorylation sites for ERK, Akt and PKA/AMPK (adenosine monophosphate-activated protein kinase)
and the binding site for MAPKs (ERK, p38) are marked with bold italics. Human sequences are denoted by h, rat sequences
by r and bovine sequences by b. All DNA sequences numbered from the first base of the start codon in the most commonly
studied splice form. Accession numbers for DNA: hnNOS, D16408; rnNOS, X59949; heNOS, M93718; beNOS, M99057;
hiNOS, L24553. Protein accession numbers: hnNOS, P29475; rnNOS, P29476; heNOS, P29474; beNOS, P29473; hiNOS,
P35228.
nNOS (neuronal nitric oxide synthase) differ from the cytokine
induced isoform iNOS (inducible nitric oxide synthase) in that
they have an extended insertion at this point that serves as an AI
element displaced by CaM binding to a spatially adjacent site
[23].
The N-terminal half of the AI, shown in bold, contains a con-
served helical region (underlined residues) that locks down the
FMN-binding domain through hydrogen bonds to both the FMN-
binding domain and the NADPH-binding domain. This prevents
conformational changes that are an obligatory part of the cata-
lytic cycle. Ser617 and Ser635 in bovine eNOS (Ser615 and Ser633 in
human eNOS) are phosphorylated by kinases [Akt (also known
as PKB (protein kinase B)) and PKA] that activate the enzyme;
Ser1179 in the inhibitory C-terminal extension is a target of the
same kinases [15–18].
Recently we reported that MAPKs bind to a pentabasic se-
quence present in eNOS but not nNOS [38]. This site, shown
in bold italics, confers 80 pM affinity for p38 and 160 nM for
ERK. The location in this regulatory region suggests interactions
between MAPKs and other modulators of eNOS activity.
The evolutionary origin of the MAPK-binding site is implied
by the frame shift in the eNOS sequence in comparison to nNOS
at the end of the conserved AI region [38]. As shown in Figure 1,
a compensating shift restores the reading frame 27 bp later in
eNOS, and the homology at the amino acid level immediately
resumes. During the 27 bp frame shift, there is however no rela-
tionship between eNOS and nNOS at the amino acid level (some
homology appears to persist at the DNA level). Divergence of
eNOS from nNOS occurred during or before the development of
amphibians, and translation of the nNOS sequence in Figure 1
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Figure 2 MS results for trypsin digest of ERK phosphorylated eNOS showing phosphorylated peptides
Potential phosphorylation sites are indicated by # symbol. Because ERK phosphorylates TP and SP motifs, the results
are uniquely consistent with Ser602, Thr46 and Ser58 phosphorylation, which can account for all the species observed.
Asterisks indicate oxidized methionines. No peptides were shared with the unphosphorylated control.
with the appropriate frame shift introduces a basic motif. It seems
plausible that these motifs arose by chance and were stabilized
during evolution by protein–protein interactions.
Phosphorylation of eNOS by ERK was detected in vitro by
measurement of ADP; the results showed that during a 1 h incub-
ation, two or three ADP were formed per eNOS monomer, sug-
gesting that multiple sites were phosphorylated. Figure 2 shows
the results of MS of tryptic digests of unphosphorylated eNOS
and eNOS phosphorylated for 15 min by ERK. Coverage was
essentially complete; 35 phosphorylated tryptic peptides were
obtained in addition to 3545 unphosphorylated peptides.
Ser602 and Thr46 were identified unambiguously as phos-
phorylation sites from the MS results alone, considering that
only serine and threonine are potential targets. In addition, the
data showed that either Ser58 or Thr62 was phosphorylated; be-
cause MAPKs phosphorylate at SP or TP sites, the third position
was unambiguously identified as Ser58. No indication of phos-
phorylation at other sites was observed.
Figure 3(A) shows the structure of the reductase portion of
nNOS, corresponding roughly to the C-terminal half of the en-
zyme [45]. No corresponding eNOS crystal structure is available,
but the two enzymes are highly homologous in this region and the
conserved structures shown should be nearly identical. The rib-
bon diagram traces the path of the backbone through the FMN,
FAD and NADPH-binding domains, with the cofactors shown
in solid render. In this conformation, the FAD and FMN isoal-
loxazines are in van der Waals contact. At the opposite edge of
the FMN-binding domain β sheet, the ends of the AI are ex-
posed at the adjacent ends of an α-helix and a β-strand; the trace
appears discontinuous because the chain is too flexible here to
have a well-defined structure. The AI helix is visible as a dis-
connected feature, and is connected to the FMN domain β sheet
by a long-disordered loop on the C-terminal side and a short-
disordered loop on the N-terminal side. The long loop carries
the MAPK-binding site close to the edge of the β-sheet and the
adjacent CaM-binding site, accounting for the CaM–MAPK com-
petition, which we previously reported [38]. Ser602 is located in
the short-disordered loop directly adjacent to the α-helical region
that precedes the AI. Ser617 is located in the AI helix, and Ser635
is in the long-disordered loop between the MAPK-binding site
and the β-strand that follows the AI. (These residues correspond
to Ser600, Ser615 and Ser633 in human eNOS.)
Figure 3(B) shows the structure of the eNOS oxygenase do-
main dimer [46,47]. The haem and BH4 (tetrahydrobiopterin)
cofactors are shown in solid render along with the Zn atom that
stabilizes the dimer. Thr46 and Ser58 are located in a disordered
region adjacent to the loops bearing the cysteine residues that
coordinate the Zn; the sites of myristoylation and palmitoylation
are further towards the N-terminus. This region of the oxygenase
domain surface is close to the point where the polypeptide chain
leaves the oxygenase domain to form the CaM-binding site, and
also reasonably close the site of haem reduction on the opposite
monomer.
The results of experiments showing the effect of ERK-
mediated phosphorylation on eNOS activity in NO synthesis and
cytochrome c reduction are summarized in Table 1. These figures
suggest inhibition of around 60 %, but the results are slightly com-
plicated by two factors. To obtain a high degree of phosphoryla-
tion, it is necessary to incubate eNOS with kinases at 22 ◦C;
during the incubation, control eNOS activity decreases slightly.
If phosphorylated eNOS is less stable than unphosphorylated
eNOS, we could overestimate inhibition slightly. A more serious
problem is the incomplete phosphorylation of eNOS. Although
we have several measures of the degree of phosphorylation (e.g.,
the results of fluorescence decay experiments), we cannot exclude
the possibility that a minority population of unphosphorylated
eNOS accounts for much of the residual activity.
We are confident that NO synthesis measured spectrophoto-
metrically through the reaction of NO with oxyhaemoglobin is
inhibited by at least 50 %. Inhibition was confirmed in end point
assays with the Griess reagent. Reduction of ferri-cytochrome c
by eNOS was monitored at 418 and 550 nm to assess the effect
of phosphorylation on electron transfer within the reductase unit.
Phosphorylation also inhibits cytochrome c reduction by at least
50 %. In both cases, it is possible that phosphorylation reduces
the activity by more than 70 %.
Figures 4(A) and 4(B) show the time course of eNOS phos-
phorylation using Western blotting with a phospho-specific
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
538 c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
ERK phosphorylates and inhibits eNOS
Figure 3 Location of phosphorylation sites in eNOS
(A) Structural cartoon of NOS reductase domains based on the nNOS reductase crystal structure [45]. The FMN-binding
domain is in blue, the FAD-binding domain green and the NADPH-binding domain is tan. Cofactors are shown in solid render,
and the residues at the N-terminal edge of the FMN-binding domain and at the ends of the AI insertion (Arg878/Arg648
and Arg829/Ser596 for nNOS/eNOS) are marked by solid render. The approximate extent and position of the disordered
regions of the AI are indicated by a drawn coil. The AI carried previously identified targets for Akt and PKA phosphorylation
as well as a MAPK-binding site and a target for ERK phosphorylation (Ser602) that also matches the target motifs of
other MAPKs. The C-terminal extension carries Ser1179, a target for Akt and PKA (see PDB 1TLL). (B) Structural cartoon
of eNOS oxygenase dimer based on crystal structures [46,47]. The direction of the backbone is indicated by colour, with
the N-terminal blue and the ribbon shading through green to tan at the C-terminal. Cofactors and substrate arginine are
shown in solid render, with haem shown in red and BH4 in yellow. The location of two ERK targets in a disordered region
at the bottom of the figure is indicated; the region is near the dimer interface. The C-terminal end of the domain is shown
emerging from the face at right; this becomes the CaM-binding site, and after a short connector joins the FMN-binding
domain shown in Figure 3(A). This domain must supply electrons to the haem at right by disengaging from the reductase
complex and re-orienting (see PDB 4NSE and 3NOS).
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Table 1 Effects of ERK catalysed phosphorylation of eNOS on activity and on the population
of eNOS conformational states characterized by FMN fluorescence lifetimes
The lifetime distributions in this table differ somewhat from those in the fits shown in Figure 5 because
they are derived from decays of the CaM-activated enzyme to correspond to NO synthase activity. The
distributions in Figure 5 show the effects of phosphorylation in the absence of CaM.
Fluorescence lifetime
(% state populations)NO synthesis Cytochrome c
(nm−1 min−1 mg−1) reduction (min−1) 90 ps 0.9 ns 4.3 ns
eNOS 110 (10) 143 (20) 53.45 20.21 26.35
eNOS + ERK 42 (7.6) 55 (5) 85 – 15
Figure 4 Time course of Ser602 phosphorylation and
dephosphoryaltion
(A) Western blots of purified eNOS after 0, 15, 30 and 60 min treatment
with ERK showing the development of a band corresponding to phos-
phorylated Ser602 when probed with phospho-specific Ser602. Control
probed with anti-eNOS shows that lanes are equally loaded and that
eNOS is not significantly lost at times up to 1 h, but at longer times
the signal from anti-eNOS is markedly reduced. (B) Plot of densitometry
from two trials of time course. (C) Western blots of BAEC lysates treated
with λ phosphatase and probed with anti-pS602 and anti-eNOS.
pS602 antibody raised to a phosphorylated target peptide and
depleted of unspecific components by treatment with unphos-
phoryalted peptide. After a lag of approximately 10 min, ERK
phosphorylates eNOS with maximum intensity obtained at about
Table 2 Rate and equilibrium constants for CaM binding to
unphosphorylated and ERK phosphorylated eNOS
−ERK +ERK
BLI (single-state)
kon (M− 1 s− 1) 1.2 × 105 1.2 × 105
koff (s− 1) 1.1 × 10− 4 3.3 × 10− 4
KD (pM) 920 2700
SPR (sequential model)
kon1 (M− 1 s− 1) 6.4 × 104 1.1 × 105
koff1 (s− 1) 2.0 × 10− 3 2.5 × 10− 3
kon2 (s− 1 8.4 × 10− 3 3.7 × 10− 3
koff2 (s-1) 1.9 × 10− 4 1.1 × 10− 4
KD (pM) 720 650
1 h. By 90 min, the control blot with anti-eNOS was significantly
lower, and this was reflected in a weaker signal with anti-pS602.
Figure 4(C) shows Western blots of BAEC lysates probed with
anti-pS602 and anti-eNOS after treatment with λ phosphatase. A
strong band from eNOS phosphorylated at Ser602 is removed
by the phosphatase over a period of 2 h, during which the anti-
eNOS signal is essentially invariant. This demonstrates that Ser602
is significantly phosphorylated in endothelial cells, and that the
anti-pS602 antibody does not bind to unphosphorylated eNOS.
We previously showed that CaM binding to unphosphorylated
eNOS was diffusion limited and that PKC inhibition of eNOS via
phosphorylation at Thr497 strongly inhibits CaM binding [27].
ERK phosphorylation of the target residues does not strongly
affect CaM binding, suggesting that PKC and ERK inhibit
eNOS via different mechanisms. Optical biosensing experiments
demonstrate near-1 nM affinities regardless of phosphorylation
state. Figures 5(A) and 5(B) show BLI traces with fits to global
single-state models for CaM binding to unphosphorylated and
phosphorylated eNOS, respectively. Rate constants are shown in
Table 2. At the concentrations examined binding can be well ap-
proximated by a single-state first-order model with remarkably
similar profiles regardless of phosphorylation. The difference in
affinity observed is entirely due to a 3-fold higher koff, though
this may not be physiologically relevant (see the Discussion
section).
Single-cycle kinetic analysis by SPR also revealed that CaM
binding of unphosphorylated eNOS in Figure 5(C) is highly sim-
ilar to phosphorylated (Figure 4D). CaM was immobilized prior
to injection of the analyte eNOS. Fits to a sequential model
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Figure 5 Optical biosensing analysis of CaM–eNOS binding
(A) BLI sensorgram of CaM binding to 0, 10.9, 31.9, 43.7 and 87.5 nM unphosphorylated eNOS. Raw data are in black; fits
to a single-state association-then-dissociation model are shown in grey. (B) Same as in (A), but for the same concentrations
of phosphorylated eNOS. (C) SPR sensorgram of single-cycle kinetics of tethered CaM binding to 6.2, 18.5, 55.6, 167
and 500 nM analyte unphosphorylated eNOS. Reference-subtracted raw data are in shown in black along with fits to a
two-state sequential model in red. (D) Same as in (C), but with phosphorylated eNOS.
(A + B↔ AB↔AB*) generate KDs similar to those determined
from BLI (Table 2), indicating that the secondary event is a minor
component.
We recently showed that iNOS passes through a series of ob-
ligatory conformational states during its catalytic cycle, includ-
ing an input state in which the FMN-binding domain is closely
associated with the FAD and NADPH-binding domains, an out-
put state in which the FMN-binding domain is associated with
the haem-containing oxygenase domain, and a series of open
conformations in which FMN is not closely coupled to other
prosthetic groups [43]. These states can be resolved by their very
different fluorescence lifetimes; eNOS and nNOS have similar
conformational states. CaM activation of eNOS and nNOS res-
ults in increased levels of the output and open states relative to
the closed input state.
Figure 6 shows fluorescence decays of unphosphorylated and
ERK-phosphorylated eNOS in the presence and absence of CaM.
ERK phosphorylation causes an increase in the input state, which
has a lifetime of 90 ps because of close coupling between FMN
and FAD, and a concomitant increase in the output state (0.9 ns
lifetime) and the open states (4.3 ns average lifetime). This effect
is in opposition to the effect of CaM binding, and accounts for
the inhibition of NO synthesis and cytochrome c reduction by
ERK-mediated phosphorylation.
The effects of ERK phosphorylation on eNOS activity and on
the distribution of conformational states characterized by FMN
fluorescence lifetimes are summarized in Table 1. The effects of
ERK phosphorylation on the conformational manifold are oppos-
ite of the principal activator, CaM. Apparent inhibition of both
NO synthesis and cytochrome c reduction is at least 60 %, and
may be greater because we are unable to phosphorylate eNOS
completely without long incubations that damage the enzyme.
Fluorescence data and information gained from phospho-specific
antibody work suggest that the enzyme is at least 75 % phos-
phorylated.
DISCUSSION
The MAPKs, ERK and p38 are believed to participate in negative
feedback signalling networks with eNOS, and good evidence in-
dicates direct phosphorylation of eNOS by ERK in BAECs [35].
Based on indirect evidence obtained in intact cells, sites have
been proposed for ERK phosphorylation including Ser116, Thr497
and Ser635 [36,37]. Of these, only Ser116 has the SP/TP motif as-
sociated with MAPK targets. Ser116 is located on the oxygenase
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
541
J. C. Salerno and others
Figure 6 Fluorescence decays of eNOS holoenzyme FMN excited at 473 nm and detected at 525 nm
The eNOS concentrations in the samples were 1 uM, and were from the same preparation. ERK phosphorylation favours
conformational states with shorter lifetimes; CaM activation produces the opposite effect and as shown here partially
reverses the effect of ERK phosphorylation. Fitting parameters were: unphosphorylated eNOS: 90 ps, 78 %; 3.65 ns, 20 %;
0.9 ns, 0.68 %; 10.1 ns, 1.6 %; c2 = 1.10. ERK phosphorylated eNOS: 80 ps, 86 %; 3.83 ns, 12.4 %; 1.1 ns 1.8 %. All
experiments were performed six times using at least two different preparations. The scattering reference was collected at
475 nm, and indicates the width of the exciting pulse.
domain, and the MAPK-binding site we recently identified [27]
is located on the AI element of the FMN-binding domain. Phos-
phorylation of other residues (Thr497, Ser635 and human cognates)
is the result of pathway dependent ERK-linked activation of other
serine–threonine kinases.
Direct in vitro phosphorylation of purified eNOS with pur-
ified ERK confirmed that eNOS is a substrate for ERK, and
further showed that phosphorylation did not require additional
scaffolds or adaptors [35]. ERK phosphorylation inhibits both
NO synthesis and cytochrome c reduction, indicating that phos-
phorylation interferes with electron transfer reactions mediated
by FMN.
Three sites of phosphorylation on eNOS were identified;
Ser602, at the N-terminal end of the AI, is spatially adjacent to
the MAPK-binding site and the CaM-binding site, and is well
positioned to interact with other control sites. A ‘lockdown’ of
the FMN-binding domain is suggested by fluorescence results
showing that phosphorylation pulls the enzyme’s conformational
distribution towards the input state. This accounts for the ob-
served inhibition, and suggests that the negatively charged phos-
phate group stabilizes the input conformation. CaM appears to
bind strongly to ERK phosphorylated eNOS, but is unable to ef-
fectively override phosphorylation imposed inhibition. Although
the results of CaM activation and ERK phosphorylation on the
fluorescence profile are fortuitously opposite ([49] and present
communication), we point out that effects on the conformational
equilibria are secondary to the changes in rates for conforma-
tional transitions. It is possible to inhibit the enzyme by locking
it into any conformation, because the mechanism depends on
conformational cycling [48].
Our previous report described in detail the complex kinet-
ics of CaM–eNOS binding [27]. In the present study, ERK-
phosphorylated eNOS demonstrated a similar CaM-binding pro-
file; diffusion-limited association, very slow dissociation and pi-
comolar affinity. A 3-fold slower dissociation rate constant in BLI
accounts for the affinity difference between unphosphorylated
and phosphorylated eNOS. The difference may be kinetically
significant (95 % confidence intervals for koff do not overlap)
but cannot account for differences in regulation of NOS activ-
ities. The difference in koff is much less pronounced in SPR
experiments and the affinities are nearly identical to the 650 pM
previously reported [27]. In contrast, phosphorylation of Thr497
by PKC interferes with CaM binding [27]. The modes of ERK
and PKC inhibition are thus entirely different: PKC prevents the
binding of an activator, while ERK interrupts the catalytic cycle.
ERK phosphorylates eNOS at Thr46, Ser58 and Ser602; the first
two of these residues are located in the N-terminal extension of
the oxygenase domain. The location of Ser602 is ideal for the
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control of FMN-mediated electron transfer, and it lies close to
the D-domain-type MAPK-binding site. The significance of Thr46
and Ser58 phosphorylation is unclear. The disordered N-terminal
region is known to participate in protein–protein interactions,
protein trafficking and myristoylation/palmitoylation. It is un-
clear that ERK bound to the AI pentabasic site can phosphorylate
sites on the oxygenase domain.
We think it unlikely that MAPKs phosphorylate residues such
as Thr497, Ser617, Ser635 and Ser1179. All these sites with the ex-
ception of Thr497 activate eNOS, and none of them has an SP
or TP target motif [50,51]. When phosphorylation of these sites
correlates with MAPK activation, it is likely that this occurs in a
pathway-dependent manner. For inhibitory events such as Thr497
phosphorylation, this might represent parallel pathways of in-
hibition. For activating events, it probably represents feedback
pathways involved in push–pull regulation.
We were surprised not to detect Ser116 phosphorylation. This
residue is located on a flexible loop near the mouth of the substrate
access channel of the oxygenase domain, is phosphorylated by
SP-directed kinases in vivo and has been linked to ERK in plaus-
ible studies [37]. Several possibilities present themselves: phos-
phorylation could be mediated by other kinases, phosphoryla-
tion by MAPKs could require additional input (e.g., prior phos-
phorylation of other sites), or phosphorylation by MAPKs could
require scaffolding components.
The tight spacing of control sites on the eNOS surface paints
a picture of a system in which eNOS is at the junction of many
signalling pathways and is an active node in the resulting network.
A simple example of multiple inputs is Thr497 phosphorylation,
which interferes with CaM binding and hence activation [24,27].
The sites associated with the AI are far more complex. Activating
kinases such as PKA and Akt phosphorylate multiple targets in
this region (12–18), which also includes the ERK/p38-binding
site, the Ser602 ERK target and the AI helix, which locks the
FMN-binding domain to the NADPH-binding domain. It is likely
that phosphorylation of these sites affects the binding of other
regulators and phosphorylation of other sites. The complexity of
the system may allow eNOS to behave more like an integrated
circuit with multiple inputs and a nuanced array of outputs than
a simple relay.
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